Last Updated : June 28, 2021 / 07:12 AM IST
Moneycontrol Daily: Your Essential 7
A daily round-up of the most interesting articles to help jump-start the day.
Market Buzz
FPIs turn net buyers in June
After remaining net sellers for two months in a row, foreign portfolio investors (FPIs) in June turned net buyers by pumping in a net Rs 12,714 crore into Indian markets. Read the details here.
Watch Out
Take a look at these key events
Today:
SAT to pass order in Franklin Templeton case.
Shares of Krishna Institute of Medical Sciences and Dodla Dairy will make debut on the BSE and NSE.
Delhi to ease COVID-19 curbs from today; gyms, hotels to reopen with 50 percent capacity
Tomorrow:India to celebrate National Statistics Day
FICCI to organise virtual event on footwear industry
Big Story
First-ever drone terror attack raises concern
In what is believed to be the first use of drones in a terror attack on an Indian military facility, two explosions took place at the Air Force base in Jammu Airport on June 27. Read here to know more.
Coronavirus Check
Third wave likely to hit India late
The chief of the government’s COVID panel has said that the coronavirus wave is likely to hit India late, offering a six to eight-month window to vaccinate all eligible beneficiaries in the country. This report has all the details.
Tech Tattle
Electricity from vibrations
Scientists have fabricated a simple, cost-effective, bio-compatible, transparent nanogenerator that can generate electricity from vibrations all around for use in optoelectronics, self-powered devices and other biomedical applications. Read here.
Auto
Airbag rule deadline extended
The road transport ministry has deferred by four months the mandatory installation of dual airbags for front seats in the existing car models, in view of the COVID-19 pandemic. Read the details here.
Tailpiece
Furore over new Alzheimers drug
Biogen's Aduhelm is the first Alzheimers medication in nearly 20 years. However, its Food and Drug Administration approval is triggering a backlash from many experts, who had warned that its supposed benefit relied on flimsy data. This report has details.
You are already a Moneycontrol Pro user.